Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
1999-10-29
2002-12-24
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C424S085100, C424S085200, C424S085400, C424S085500, C424S184100, C424S192100, C424S093100, C424S093700, C424S534000, C424S577000, C424S578000, C435S002000, C435S325000, C435S375000, C435S377000, C514S002600, C514S008100, C514S885000
Reexamination Certificate
active
06497876
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a dendritic cell activation factor, to methods of enhancing a lymphocyte-mediated immune response in vivo, and to dendritic cell populations useful in the manipulation of cellular and humoral immune responses.
BACKGROUND OF THE INVENTION
Vaccination is an efficient means of preventing death or disability from infectious diseases. The success of this method in the field of infectious disease has also stimulated interest in utilizing vaccination in the treatment or prevention of neoplastic disease. Despite the successes achieved with the use of vaccines, however, there are still many challenges in the field of vaccine development. Parenteral routes of administration, the numbers of different vaccinations required and the need for, and frequency of, booster immunizations all impede efforts to control or eliminate disease.
One such difficulty is lack of immunogenicity in an antigen, i.e., the antigen is unable to promote an effective immune response against the pathogen. In addition, certain antigens may elicit only a certain type of immune response, for example, a cell-mediated or a humoral response. Adjuvants are substances that enhance, augment or potentiate an immune response, and can in some instances be used to promote one type of immune response over another. Although numerous vaccine adjuvants are known, alum is the only adjuvant widely used in humans.
Dendritic cells are a heterogeneous cell population with distinctive morphology and a widespread tissue distribution (Steinman, R. M.,
Annu. Rev. Immunol
., 9:271-296, 1991). Dendritic cells are referred to as “professional” antigen presenting cells, and have a high capacity for sensitizing MHC-restricted T cells. Thus, there is growing interest in using dendritic cells ex vivo as tumor or infectious disease vaccine adjuvants (see, for example, Romani, et al.,
J. Exp. Med
., 180:83, 1994). Therefore, an agent that enhanced the ability of dendritic cells to stimulate an immune response would be of wide importance.
SUMMARY OF THE INVENTION
The present invention pertains to a method of activating dendritic cells to enhance antigen presenting capacity. The activated, antigen-presenting dendritic cells of the invention are useful as vaccine adjuvants.
The invention also provides a method of generating large quantities of antigen-presenting dendritic cells ex vivo. Following collection of an individual's CD34
+
hematopoietic progenitors and stem cells, cytokines such as granulocyte-macrophage colony stimulating factor (GM-CSF) and flt-3 ligand (flt3-L) can be used to expand the cells in vitro and to drive them to differentiate into cells of the dendritic cell lineage. Cytokines can also be used to increase the numbers of CD34
+
cells in circulation prior to collection. The resulting dendritic cells are exposed to an antigen one wishes to elicit an immune response against, and allowed to process the antigen (this procedure is sometimes referred to in the art as “antigen-pulsing”). The antigen-pulsed (or antigen-expressing) dendritic cells are then activated with a CD40 binding protein, and subsequently administered to the individual.
An alternate method for preparing dendritic cells that present antigen is to transfect the dendritic cells with a gene encoding an antigen or a specific polypeptide derived therefrom. Once the dendritic cells express the antigen in the context of MHC, the dendritic cells are activated with a CD40 binding protein, and subsequently administered to the individual to provide a stronger and improved immune response to the antigen.
The activated antigen-presenting dendritic cells can also be used as a vaccine adjuvant and can be administered prior to, concurrently with or subsequent to antigen administration. Moreover, the dendritic cells can be administered to the individual prior to, concurrently with or subsequent to administration of cytokines that modulate an immune response, for example a CD40 binding protein (i.e., soluble CD40L), or a soluble CD83 molecule. Additional useful cytokines include, but are not limited to, Interleukins (IL) 1, 2, 4, 5, 6, 7, 10, 12 and 15, colony stimulating factors (CSF) such as GM-CSF, granulocyte colony stimulating factor (G-CSF), or GM-CSF/IL-3 fusion proteins, or other cytokines such as TNF-&agr; or c-kit ligand. Moreover, biologically active derivatives of these cytokines; and combinations thereof will also be useful.
The invention also provides for the ex vivo preparation of antigen-specific T cells. Following the procedures described above for preparing large numbers of antigen-presenting dendritic cells ex vivo, the collected antigen-presenting dendritic cells are used to generate antigen-specific T cells from naive T cells that have been collected from the individual. After the antigen has been adequately presented to the T cells generated, the antigen-specific T cells can be administered to the individual.
REFERENCES:
patent: 5525708 (1996-06-01), Nocka
patent: 5540926 (1996-07-01), Aruffo
patent: 5633234 (1997-05-01), August et al.
patent: 5994126 (1999-11-01), Steinman et al.
patent: 6087329 (2000-07-01), Armitage
patent: 93/08207 (1993-04-01), None
patent: 94/28113 (1994-12-01), None
Grouard et al. J. Immunol. 155: 3345-3352(1995).*
Calland et al. Immunol. Today 14: 559-564 (1993).*
Noelle et al. Immunol. Today 13: 431-433(1992).*
Siena et al. SPTL. Hematol. 23: 1463-1471 (1995).*
Morse et al. Cancer Research 58: 2965-2968 (1998).*
Callard et al. Immunol. Today 14: 559-564 (1993).*
Ye et al. Am. Soc. Hematol (1995).*
Gee et al. Keystone BMT Symposia (1996).*
Siena et al. Exptl. Hematol. 23: 1463-1471 (1995).*
Caux et al. J. Exp Med. 180: 1263-1272 (1994).*
Sallusto et al. J Exp Med 179:: 1109-1118(1994).*
Galy et al. Immunity 3:459-473 (1995).*
Grouard et al.,J. Immunol. 155:3345, 1995.
Van der Berg et al.,Immunol. 88:294, 1996.
Peguet-Navarro et al.,J. Immunol155:4241, 1995.
Paglia et al.,J. Exp. Med. 178:1893, 1993.
Levya-Cobian et al.,Immunology Letters43:29, 1994.
Girolomani et al.,Eur. J. Dermatol. 5:12, 1995.
Jaiswal et al.,Int'l. Immunol. 8:275, 1996.
Koch et al.,J. Exp. Med. 184:741, 1996.
Caux et al.,J. Exp. Med. 180:1263, 1994.
Sallusto et al.,J. Exp. Med. 179:1109, 1994.
Ye et al., American Society of Hematology 37th Annual Meeting.
Gee et al., Keystone Mone Marrow Transplantation Symposia 1996.
Maraskovsky Eugene
McKenna Hilary J.
Gambel Phillip
Henry Janis C.
Immunex Corp.
LandOfFree
Method of stimulating an immune response with activated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of stimulating an immune response with activated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of stimulating an immune response with activated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2941552